Business Description
ResMed Inc
NAICS : 339112
SIC : 3841
ISIN : US7611521078
Total Employee Number:
10,600Compare
Compare
Traded in other countries / regions
RMD.USARMD.AustraliaRMEA.Germany0KW4.UKRMD.MexicoRMD.Austria1RMD.ItalyR1MD34.Brazil Index Membership
S&P 500Russell 1000Russell 3000MSCI World Index IPO Date
1995-06-02Description
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.78 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.13 | |||||
Debt-to-EBITDA | 0.38 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 10.8 | |||||
Beneish M-Score | -2.57 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 10.6 | |||||
3-Year EBITDA Growth Rate | 17.2 | |||||
3-Year EPS without NRI Growth Rate | 20.1 | |||||
3-Year FCF Growth Rate | 43.3 | |||||
3-Year Book Growth Rate | 17.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 8.79 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 5.43 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 14.29 | |||||
9-Day RSI | 31.8 | |||||
14-Day RSI | 42.28 | |||||
3-1 Month Momentum % | 16.87 | |||||
6-1 Month Momentum % | -6.38 | |||||
12-1 Month Momentum % | -18.12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.1 | |||||
Quick Ratio | 2.42 | |||||
Cash Ratio | 1.05 | |||||
Days Inventory | 154.28 | |||||
Days Sales Outstanding | 62.85 | |||||
Days Payable | 45.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.13 | |||||
Dividend Payout Ratio | 0.21 | |||||
3-Year Dividend Growth Rate | 10.9 | |||||
Forward Dividend Yield % | 1.21 | |||||
5-Year Yield-on-Cost % | 1.71 | |||||
3-Year Average Share Buyback Ratio | 0.6 | |||||
Shareholder Yield % | 3.13 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 61.06 | |||||
Operating Margin % | 33.76 | |||||
Net Margin % | 26.95 | |||||
EBITDA Margin % | 38.08 | |||||
FCF Margin % | 28.81 | |||||
OCF Margin % | 31.94 | |||||
ROE % | 24.19 | |||||
ROA % | 17.82 | |||||
ROIC % | 24.09 | |||||
3-Year ROIIC % | 86.4 | |||||
ROC (Joel Greenblatt) % | 90.83 | |||||
ROCE % | 26.17 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 20.93 | |||||
Forward PE Ratio | 18.08 | |||||
PE Ratio without NRI | 19.54 | |||||
Shiller PE Ratio | 36 | |||||
Price-to-Owner-Earnings | 20.09 | |||||
PEG Ratio | 1.28 | |||||
PS Ratio | 5.64 | |||||
PB Ratio | 4.78 | |||||
Price-to-Tangible-Book | 9.77 | |||||
Price-to-Free-Cash-Flow | 19.56 | |||||
Price-to-Operating-Cash-Flow | 17.65 | |||||
EV-to-EBIT | 16.16 | |||||
EV-to-Forward-EBIT | 15.15 | |||||
EV-to-EBITDA | 14.33 | |||||
EV-to-Forward-EBITDA | 14.05 | |||||
EV-to-Revenue | 5.46 | |||||
EV-to-Forward-Revenue | 5.26 | |||||
EV-to-FCF | 18.94 | |||||
Price-to-GF-Value | 0.82 | |||||
Price-to-Projected-FCF | 1.57 | |||||
Price-to-DCF (Earnings Based) | 0.86 | |||||
Price-to-DCF (FCF Based) | 0.92 | |||||
Price-to-Median-PS-Value | 0.78 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.22 | |||||
Price-to-Graham-Number | 2.91 | |||||
| Price-to-Net-Current-Asset-Value | 16.2 | |||||
Earnings Yield (Greenblatt) % | 6.19 | |||||
FCF Yield % | 5.17 | |||||
Forward Rate of Return (Yacktman) % | 19.29 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:RMD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ResMed Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 5,653.443 | ||
| EPS (TTM) ($) | 10.43 | ||
| Beta | 0.5128 | ||
| 3-Year Sharpe Ratio | 0.48 | ||
| 3-Year Sortino Ratio | 0.79 | ||
| Volatility % | 28.67 | ||
| 14-Day RSI | 42.28 | ||
| 14-Day ATR ($) | 6.391041 | ||
| 20-Day SMA ($) | 228.748 | ||
| 12-1 Month Momentum % | -18.12 | ||
| 52-Week Range ($) | 180.265 - 284.87 | ||
| Shares Outstanding (Mil) | 144.25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ResMed Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ResMed Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2027 | 2027-01-29 16:30 | In 140 days | ||
| Second quarter earnings results for 2027 | 2027-01-29 | In 139 days | ||
| General meeting for 2026 | 2026-11-19 15:00 | In 69 days | ||
| First quarter earnings conference call for 2027 | 2026-10-30 16:30 | In 49 days | ||
| First quarter earnings results for 2027 | 2026-10-30 | In 48 days | ||
| 24th Annual Morgan Stanley Global Healthcare Conference | 2026-09-15 10:00 | In 4 days | ||
| USD 0.660000 Cash Dividend | 2026-08-20 | 230.65 (+4.37%) | ||
| Annual report for 2026 | 2026-08-13 | 226.00 (+3.32%) | ||
| Fourth quarter earnings conference call for 2026 | 2026-08-06 16:30 | 224.03 (+0.91%) | ||
| Fourth quarter earnings results for 2026 | 2026-08-06 | 224.03 (+0.91%) |
Show
Entries
ResMed Inc Frequently Asked Questions
What is ResMed Inc(RMD)'s stock price today?
The current price of RMD is $218.27. The 52 week high of RMD is $284.87 and 52 week low is $180.27.
When is next earnings date of ResMed Inc(RMD)?
The next earnings date of ResMed Inc(RMD) is 2026-10-30 Est..
Does ResMed Inc(RMD) pay dividends? If so, how much?
The Dividend Yield %  of ResMed Inc(RMD) is 1.13% (As of Today), Highest Dividend Payout Ratio of ResMed Inc(RMD) was 0.47. The lowest was 0.21. And the median was 0.29. The  Forward Dividend Yield % of ResMed Inc(RMD) is 1.21%. For more information regarding to dividend, please check our Dividend Page.
Guru Commentaries on NYSE:RMD
Airlie Australian Share Fund
Neutral
2026 Q2
What the manager wrote
Resmed was mentioned as a portfolio holding that has begun to re-rate but remains attractively priced and offers strong EPS growth. The letter discusses the changing market dynamics and how Resmed, along with other holdings, is positioned to benefit from these shifts. However, there is no explicit bullish or bearish argument made regarding Resmed's future performance.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers